First patients test new pill targeting a key cancer mutation
NCT ID NCT02073994
Summary
This first-in-human study tested a new oral drug, AG-120, designed to target a specific genetic flaw (IDH1 mutation) found in several advanced solid tumors, including certain brain, bile duct, and bone cancers. The main goals were to find the safest and most effective dose and to see how the body processes the drug. It enrolled 174 adults whose cancers had progressed after standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Scottsdale, Arizona, 85258, United States
-
Study site
Los Angeles, California, 90095, United States
-
Study site
Aurora, Colorado, 80045, United States
-
Study site
Miami, Florida, 33136, United States
-
Study site
Baltimore, Maryland, 21218, United States
-
Study site
Boston, Massachusetts, 02215, United States
-
Study site
New York, New York, 10065, United States
-
Study site
Nashville, Tennessee, 37203, United States
-
Study site
Dallas, Texas, 75390, United States
-
Study site
Houston, Texas, 77030, United States
-
Study site
San Antonio, Texas, 78229, United States
-
Study site
Villejuif, 94800, France
Conditions
Explore the condition pages connected to this study.